Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wellsite,
Thanks for the thoughtful post.
By-Health giving nothing away in reply to an investors question.
BY-HEALTH Shareholder 2020-12-08
On November 17, 2016, the company announced that it will cooperate with the Dutch DSM Group to jointly develop new functional products for cardiovascular health. The research and development cooperation will take "Fruitflow" as the main direction to develop new functional products that contribute to cardiovascular health. What is the progress of this cooperative research and development? Four years have passed, is there any product launch?
BY-HEALTH: Reply 2020-12-12
Hello! The company continues to focus on innovative research and development of “new functions, new raw materials, and new technologies”, has made corresponding research and development reserves, and will launch new products in a timely manner based on the approval of the national food safety supervision and management department and market demand. Thank you for your attention.
http://guba.eastmoney.com/news,300146,986381252.html
DP
Strategy
1. Keep the faith. DVT, Pollution, muscle synthesis, blood pressure, Covid, what isn’t there to like and more importantly, what’s next....
2. Trade a few on news.
3. Sell the lot as soon as options are exercised by BOD or SL starts unloading.
4. In absence of 3. hold majority until takeover, sell some to manage tax bill. If we see a repeat of 2010 and an RNS saying no reason for rise, sell as many as possible.
5. Be respectful to others, everyone is entitled to their opinion.
W$
Hi Wellsite,
That's a very good holding and sure you will be rewarded in case the SP goes higher in case of a take over. So if there is no take over, what is your exit strategy?
CB
Felix obviously likes dealing with IF, that’s all that matters atm
W£
:-)
So you have 50 Million shares Wellsite !!! post up your address I will send around an ambulance.
I agree. Totally the wrong person for leading this type of company. I'm surprised the major shareholders have not removed him.
He has been paid handsomely considering what he has delivered . He doesn't have a science background , he was the wrong choice for the job. As for options they should be performance related , hence they should have lapsed with him receiving nothing imo.
Gixer
he wouldn’t buy the shares, he would just get the delta between strike and exercise price. The tax position is unknown as he may get entrepreneur tax rates.
Agreed 2p isn’t exciting, 5p would be more life changing.
- would make my holding worth £2.5 M gross
W$$$$$
minus initial purchase price.
I seem to be missing 7m somewhere as he appears to have 50m
So selling the company @ 2p, as everhopeful suggests, is not that beneficial to him. IMO
But who knows what the SP will be by April 2022.
Gixer
so in essence he gets 350£k fo every penny rise above where we are now - we don’t know what the other criteria are in order to exercise. Subject to tax 3 to 5p would net him a mill.
W$
At this moment, and please someone correct me if I am wrong, he has 10m (from memory) that are exercisable at a price of 0.55p
25m available to him from April 2022 @0.3p
and
8m at a price of 2.8p (i think these are due to run out soon)
Gixer
his options are where the money is for him
W$
everhopeful, If as you say "he is just a taker" then he would be taking very little if he sold just now for 2p.
From memory he has 10m shares and half of them (5m) are for his kids. Be lucky if that got them through Uni.
thanks for the research Gixer.
Re To and what price , I said that IF would take 2p because I do not think his heart is in this business he is just a taker , hope that doesn't happen . Someone mentioned 22p , bring it on . 9 years ago I was saying 33p. been under water ever since.
PS still not got anyone to buy FF despite giving away pills and them approving of the results , why is this so hard ?
Hi Gixer,
Thanks for your thoughtful response. I agree that the news of China will fly the PXS, which was shown with the recent China news. My doubt is that it will be picked by By-Health or somebody else before it will hit the prospective share price. It is always to have a nice and constructive discussion from either side of the fence. However it is not nice to attack people and pick up spelling correction as some people do here (not you gixer).
Steve, last year was £222k so I think £500k might be pushing it a bit even although they did say "Strong start to the 2020/21 financial year for this business, with first quarter revenues substantially ahead of the comparative quarter in 2019/20." WRT Dsm revenue.
Not long till we find out
colbaltblue, in reply to your point 1.
I agree that there will be a slight delay in payment between By-health ordering Fruitflow from DSM and the cash arriving in PXS bank account but that would depend on the payment term if any DSM give By-Health. By-Health will have to order Fruitflow before any products hit the shelves.
"If a successful blue cap health claim is achieved for Fruitflow in China it would currently be expected to result in some significant recurring orders for Fruitflow, at a multiple of current total sales values."
I assume there will be no change to the AA for By-Health purchases so would still give PXS "a multiple of current total sales values" all be it not in a one off payment.
2. For sure there will be holder selling into any rise, especially ones who got in at the lows. Volume is low but you only need to look back a few weeks when FF+ in China was announced to see what an increase in volume can do to the SP.
All IMO though.
Steve. In order to progress that patent to a commercial health claim, an awful lot more spending on clinical testing would be necessary. Very frustrating, but it's pone of the many things I refer to when I say that cash generation could unlock so much more. ATB
The priority for me is to see the company become cash generative, which would end the perennial constraint on ambition. When that happens, many things become possible, things that posters here accuse the company of not doing. I believe that the retail arm could have real potential.
DD77. Rare that a poster regards myself and Colb in the same manner !!
Yeah, errm, luv you too :-)
gixer, I'm always happy to engage with a poster who never makes this a personal issue. I regard Fruitflow as a superb product and I've been using it for many years and will continue to use it. I have always regretted the fact that it is still not as well known as it should be and that it has not been driven harder into the professional and public arena.
To respond to your points:
1) As far as I understand the announcement in 2019, By-health will have a range of Fruitflow related products available via various outlets post blue cap. We don't know much more but the indication is that trials are progressing satisfactorily. I'm assuming that the supply of FF will be acquired via DSM and therefore the share to Provexis is unknown outside of the people party to the arrangements. Therefore, the eventual benefit to the bottom line of PXS will come via an agreed distribution from DSM. This will only occur after prospective sales in China, hence the potential delay IMO.
2) More of a gut feeling but I've seen the collective sigh of relief from other "lifers" in other shares when, after many years, a SP actually begins to rise and people can recover some cash. In addition, where will the NEW buyers come from? Volumes tell me that there is little appetite for this share at the moment and AIM has changed enormously in the last 5 years. It is now very much a wild west casino for short-termers looking for a quick buck
DP64, I know its always good to have an exit strategy but with PXS I don't, not yet anyway, but I doubt very much I would be selling in "one go".
I have a few shares but far from a significant holder unfortunately.
DP64, DD77 and alfista. Thanks.
Hi Gixer,
Just to say you another thanks for your wonderful research. Just matter of interest what price will you exit as you are one of the significant share holder. Are you planning to exit phase by phase or just at one go?
Cob,
I am here before 2009, so longer than you. You probably very busy in checking spelling and attacking people to get an attention. Keep it up.